SK-MEL-28细胞

SK-MEL-28/SK-MEL-28细胞系/SK-MEL-28细胞株/SK-MEL-28人恶性黑色素瘤细胞

Cell line name SK-MEL-28

Synonyms SK-Mel-28; SK.MEL.28; SK-MEL 28; SK MEL-28; SK MEL 28; SK Mel 28; SKMel-28; SKMEL-28; SK-MEL28; SK-Mel28; SK Mel28; SKMEL28; SKMel28; SKmel28; SKML-28; SK28; AU-Mel; P-36; P36

Accession CVCL_0526

Resource Identification Initiative To cite this cell line use: SK-MEL-28 (RRID:CVCL_0526)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: MD Anderson Cell Lines Project.

Part of: NCI-60 cancer cell line panel.

From: Memorial Sloan Kettering Cancer Center; New York; USA.

Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-524.

Population: Caucasian.

Characteristics: Lightly pigmented.

Doubling time: 27 hours (PubMed=7718330); 72 hours (PubMed=12479222); 26.9 hours (PubMed=20406486); 35.1 hours (NCI-DTP=SK-MEL-28).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Array-based CGH.

Omics: CNV analysis.

Omics: Deep exome analysis.

Omics: Exosome proteome analysis.

Omics: Deep proteome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: Fluorescence phenotype profiling.

Omics: lncRNA expression profiling.

Omics: Metabolome analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Derived from site: In situ; Skin; UBERON=UBERON_0002097.

Cell type: Melanocyte of skin; CL=CL_1000458.

PubMed=6582512; DOI=10.1073/pnas.81.2.568; PMCID=PMC344720

Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.

Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.

Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

 

PubMed=2983346; DOI=10.1073/pnas.82.5.1470; PMCID=PMC397284

Dracopoli N.C., Houghton A.N., Old L.J.

Loss of polymorphic restriction fragments in malignant melanoma: implications for tumor heterogeneity.

Proc. Natl. Acad. Sci. U.S.A. 82:1470-1474(1985)

 

Patent=US4591572

Mattes M.J., Thomson T.M., Old L.J., Lloyd K.O.

Pigmentation associated, differentiation antigen of human melanoma and autologous antibody.

Patent number US4591572, 27-May-1986

 

PubMed=3518877; DOI=10.3109/07357908609038260

Fogh J.

Human tumor lines for cancer research.

Cancer Invest. 4:157-184(1986)

 

PubMed=3335022

Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Cancer Res. 48:589-601(1988)

 

PubMed=1716514

Albino A.P., Davis B.M., Nanus D.M.

Induction of growth factor RNA expression in human malignant melanoma: markers of transformation.

Cancer Res. 51:4815-4820(1991)

 

PubMed=2041050; DOI=10.1093/jnci/83.11.757

Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D., Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.

Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.

J. Natl. Cancer Inst. 83:757-766(1991)

 

PubMed=2068080; DOI=10.1073/pnas.88.14.6028; PMCID=PMC52015

Cornil I., Theodorescu D., Man S., Herlyn M., Jambrosic J.A., Kerbel R.S.

Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression.

Proc. Natl. Acad. Sci. U.S.A. 88:6028-6032(1991)

 

PubMed=7999427; DOI=10.1016/0959-8049(94)90188-0

Marshall E.S., Matthews J.H.L., Shaw J.H.F., Nixon J., Tumewu P., Finlay G.J., Holdaway K.M., Baguley B.C.

Radiosensitivity of new and established human melanoma cell lines: comparison of [3H]thymidine incorporation and soft agar clonogenic assays.

Eur. J. Cancer 30A:1370-1376(1994)

 

PubMed=7718330; DOI=10.1016/0959-8049(94)00472-H

Baguley B.C., Marshall E.S., Whittaker J.R., Dotchin M.C., Nixon J., McCrystal M.R., Finlay G.J., Matthews J.H.L., Holdaway K.M., van Zijl P.L.

Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer.

Eur. J. Cancer 31A:230-237(1995)

 

PubMed=9354451

Castellano M., Pollock P.M., Walters M.K., Sparrow L.E., Down L.M., Gabrielli B.G., Parsons P.G., Hayward N.K.

CDKN2A/p16 is inactivated in most melanoma cell lines.

Cancer Res. 57:4868-4875(1997)

 

PubMed=9466661; DOI=10.1002/(SICI)1097-0215(19980209)75:4<590::AID-IJC16>3.0.CO;2-D

White C.A., Thomson S.A., Cooper L.T., van Endert P.M., Tampe R., Coupar B., Qiu L., Parsons P.G., Moss D.J., Khanna R.

Constitutive transduction of peptide transporter and HLA genes restores antigen processing function and cytotoxic T cell-mediated immune recognition of human melanoma cells.

Int. J. Cancer 75:590-595(1998)

 

PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N

Walker G.J., Flores J.F., Glendening J.M., Lin A.H.-T., Markl I.D.C., Fountain J.W.

Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.

Genes Chromosomes Cancer 22:157-163(1998)

 

PubMed=10700174; DOI=10.1038/73432

Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.

Systematic variation in gene expression patterns in human cancer cell lines.

Nat. Genet. 24:227-235(2000)

 

PubMed=10766161

Tsao H., Zhang X., Fowlkes K., Haluska F.G.

Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.

Cancer Res. 60:1800-1804(2000)

 

PubMed=11016658

Girnita L., Girnita A., Brodin B., Xie Y.-T., Nilsson G., Dricu A., Lundeberg J., Wejde J., Bartolazzi A., Wiman K.G., Larsson O.

Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact.

Cancer Res. 60:5278-5283(2000)